Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Adenocarcinoma × aflutinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 29 NSCLC 8 Meningeal Carcinomatosis 4 Brain Neoplasms 4 Adenocarcinoma of Lung 4 Lung Neoplasms 3 Respiratory Tract Neoplasms 1 Non Small Cell Lung Cancer NSCLC 1 Neoplasm, Residual 1 Multiple Primary Lung Cancers 1 Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer 1 EGF-R Positive Non-Small Cell Lung Cancer 1 Carcinoma 1 Bronchial Neoplasms 1 Advanced Non-small Cell Lung Cancer 1 Advanced NSCLC Patients With T790M 1 Advanced NSCLC 1 Advanced Lung Cancer 1 Adenocarcinoma 1

Interventions

Oxaliplatin 42 Gemcitabine 41 Fluorouracil 37 pembrolizumab 29 Capecitabine 29 Leucovorin 26 Docetaxel 25 Cisplatin 24 Paclitaxel 21 Carboplatin 18 Bevacizumab 17 Irinotecan 16 130-nm albumin-bound paclitaxel 16 Radiotherapy 15 Pemetrexed 15 Nivolumab 13 Albumin-Bound Paclitaxel 13 Cyclophosphamide 10 Ramucirumab 9 zolbetuximab 7 Trastuzumab 7 Radiosurgery 7 Drug Therapy 7 trastuzumab deruxtecan 6 cemiplimab 6 Taxes 6 Erlotinib Hydrochloride 6 Blood Specimen Collection 6 durvalumab 5 Sorafenib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04401059 2023-12-27

SELECT-2

Hangzhou Normal University

Phase 4 Recruiting

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡